ICH E6(R3) in effect: transforming quality management for cell and gene therapy trials
With current manufacturing capacity covering only 5%-10% of what's needed cell and gene therapy (CGT) commercialisation over the next decade, the release of ICH E6(R3) couldn't come at a more critical moment.
